Kraj: Irlandia
Język: angielski
Źródło: HPRA (Health Products Regulatory Authority)
MORPHINE HYDROCHLORIDE DIHYDROCODEINE HYDROCHLORIDE PAPAVERINE HYDROCHLORIDE
Martindale Pharmaceuticals Ltd
MORPHINE HYDROCHLORIDE DIHYDROCODEINE HYDROCHLORIDE PAPAVERINE HYDROCHLORIDE
15.4, 1.2, Milligram
Solution for Injection
Withdrawn
2008-04-14
PART II SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Omnopon Injection 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each 1 ml contains Papaveretum BP 15.4 mg, equivalent to: For excipients, see 6.1. 3 PHARMACEUTICAL FORM Solution for injection 4 CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Pre-operative medication. As an analgesic in the relief of moderate to severe pain. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION For subcutaneous or intramuscular injection. _Adults_ The usual dosage by sc or im injection is 7.7-15.4mg (0.5 to 1.0ml) repeated every 4 hours if necessary. _Elderly and debilitated patients_ The elderly are more sensitive to the action of narcotic analgesics. The initial dose should not exceed 7.7mg (0.5ml). _Children 1-12 years_ The usual dose by sc or im injection is 0.154-0.231mg/kg (0.01-0.015ml/kg) body weight. _Children 1-12 months_ The usual dose by sc or im injection is 0.1155-0.154mg/kg (0.0075-0.01ml/kg) body weight. _Neonates aged up to 1 month_ The usual dose by sc or im injection is 0.1155mg/kg (0.0075ml/kg) body weight. Anhydrous morphine (as Morphine Hydrochloride Ph. Eur.) 10 mg Papaverine Hydrochloride Ph. Eur. 1.2 mg Codeine Hydrochloride Ph. Eur. 1.04 mg IRISH MEDICINES BOARD ________________________________________________________________________________________________________________________ _Date Printed 28/07/2006_ _CRN 2026140_ _page number: 1_ 4.3 CONTRAINDICATIONS o Coma. o Hypersensitivity to any of the products ingredients. o Acute respiratory depression or chronic obstructive airways disease. o Asthma (during an attack). o Acute alcoholism. o Head injuries or increased intracranial pressure. o Heart failure secondary to lung disease. o Risk of paralytic ileus. o Phaeochromocytoma. o Current use of monoamine oxidase inhibitors or within two weeks of their w Przeczytaj cały dokument